Back to top

messenger-rna: Archive

Sundeep Ganoria

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?

Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.

MRNANegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change

Sundeep Ganoria

Can Moderna's First Cancer Therapy Win FDA Approval in 2027?

MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.

MRNANegative Net Change SNYNegative Net Change PFENegative Net Change MRKNegative Net Change

Zacks Equity Research

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.

MRNANegative Net Change MRKNegative Net Change ABUSPositive Net Change